MESSAI.iO

AI summary

95% confidence

MES research with standard focus on bioelectrochemical. Biofilms are highly tolerant to antimicrobial agents and adverse environmental conditions being important reservoirs for...

Generated by MESSAI extraction pipeline · review against source PDF

Extraction

Reported parameters

No values extracted from this paper yet.

No 3D model is mapped to this paper yet. Parameter ranges above still place reported values on the literature distribution.

Abstract

Biofilms are highly tolerant to antimicrobial agents and adverse environmental conditions being important reservoirs for chronic and hard-to-treat infections. Nanomaterials exhibit microbiostatic/microbicidal/antipathogenic properties and can be also used for the delivery of antibiofilm agents. However, few of the many promising leads offered by nanotechnology reach clinical studies and eventually, become available to clinicians. The aim of this paper was to review the progress and challenges in the development of nanotechnology-based antibiofilm drug-delivery systems. The main identified challenges are: most papers report only in vitro studies of the activity of different nanoformulations; lack of standardization in the methodological approaches; insufficient collaboration between material science specialists and clinicians; paucity of in vivo studies to test efficiency and safety.

Keywords

Drug deliveryBench to bedsideNanotechnologyStandardizationIntensive care medicineRisk analysis (engineering)

Identifiers

DOI
10.2217/fmb-2019-0251
Journal
Future Microbiology
Year
2020